Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2000;2000(2):CD001131.
doi: 10.1002/14651858.CD001131.

Pharmacological interventions for spasticity following spinal cord injury

M Taricco  1 , R Adone, C Pagliacci, E Telaro
Affiliations

Pharmacological interventions for spasticity following spinal cord injury

M Taricco et al. Cochrane Database Syst Rev. 2000.

Abstract

Background: Spasticity is a major health problem for patients with a spinal cord injury (SCI) that limits patients' mobility and affects independence in activities of daily living and work. Spasticity may also cause pain, loss of range of motion, contractures, sleep disorders and impair ambulation in patients with an incomplete lesion. The effectiveness of available drugs is still uncertain and they may cause adverse effects. Assessing what works in this area is complicated by the lack of valid and reliable measurement tools. The aim of this systematic review is to critically appraise and summarise existing information of the effectiveness of available treatments and to identify areas where further research is needed.

Objectives: To assess the effectiveness and safety of Baclofen, Dantrolene, Tizanidine and any other drugs for the treatment of long term spasticity in SCI patients as well as the effectiveness and safety of different routes of administration of Baclofen.

Search strategy: We searched the Injuries Group specialised register, the Cochrane Controlled Trials Register, MEDLINE, EMBASE and CINHALH up to 1998. Drug companies and experts active in the area were also contacted.

Selection criteria: All parallel and crossover RCTs including spinal cord injury patients complaining of "severe spasticity". Studies where less than 50% of patients had a spinal cord injury were excluded.

Data collection and analysis: Methodological quality of studies (allocation concealment, blinding, patients characteristics, inclusion and exclusion criteria; interventions; outcomes; lost to follow up) was independently assessed by two investigators. The heterogeneity among studies did not allow quantitative combination of results.

Main results: Nine out of 53 studies met the inclusion criteria. Study design was: 8 cross over, 1 parallel-group trial. Two studies (14 SCI patients), showed a significant effect of intrathecal baclofen in reducing spasticity (Ashworth Score and ADL performances), compared to placebo, without any side effect. The study comparing tizanidine to placebo (118 SCI patients) showed a significant effect of tizanidine in improving Ashworth Score but not in ADL performances. Tizanidine group reported significant rates of adverse effects (drowsiness, xerostomia). For the other drugs (Gabapentine, Clonidine, Diazepam, Amytal and oral Baclofen ) the results do not provide evidence for a clinical significant effectiveness.

Reviewer's conclusions: There is insufficient evidence to assist clinicians in a rational approach to antispastic treatment for SCI. Further research is urgently needed to improve the scientific basis of patient care.

PubMed Disclaimer

Conflict of interest statement

None known.

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

References to studies included in this review

Burke 1971 {published data only}
    1. Burke D, Gillies JD, Lance JW. An objective assessment of a gamma aminobutyric acid derivative in the control of spasticity. Proceedings of the Australian Association of Neurology 1971;8:131‐4. - PubMed
    1. Jones RF, Burke D, Marosszeky JE, Gillies JD. A new agent for the control of spasticity. Journal of Neurology, Neurosurgery and Psychiatry 1970;33(4):464‐8. - PMC - PubMed
Corbett 1972 {published data only}
    1. Corbett M, Frankel HL, Michaelis L. A double blind, cross‐over trial of valium in the treatment of spasticity. Paraplegia 1972;10:19‐22. - PubMed
Gruenthal 1997 {published data only}
    1. Gruenthal M, Mueller M, Olson WL, Priebe MM, Sherwood AM, Olson WH. Gabapentin for the treatment of spasticity in patients with spinal cord injury. Spinal Cord 1997;35(10):686‐9. - PubMed
Hugenholtz 1992 {published data only}
    1. Hugenholtz H, Nelson RF, Dehoux E, Bickerton R. Intrathecal baclofen for intractable spinal spasticity‐a double blind crossover study in eight patients. Canadian Journal of Neurological Sciences 1992;19:188‐95. - PubMed
Kravitz 1992 {published data only}
    1. Kravitz HM, Corcos DM, Hansen G, Penn RD, Cartwright RD, Gianino J. Intrathecal baclofen. Effects on nocturnal leg muscle spasticity. American Journal of Physical Medicine and Rehabilitation 1992;71(1):48‐52. - PubMed
Nance 1994 {published data only}
    1. Nance PW. A comparison of clonidine, cyproheptadine and baclofen in spastic spinal cord injured patients. Journal of the American Paraplegia Society 1994;17:150‐6. - PubMed
Penn 1989 {published data only}
    1. Penn RD, Savoy SM, Corcos D, Latash M, Gottlieb G, Parke B, et al. Intrathecal baclofen for severe spinal spasticity. New England Journal of Medicine 1989;320(23):1517‐21. - PubMed
Stewart 1991 {published data only}
    1. Stewart JE, Barbeau H, Gauthier S. Modulation of locomotor patterns and spasticity with clonidine in spinal cord injured patients. Canadian Journal of Neurological Sciences 1991;18:321‐32. - PubMed

References to studies excluded from this review

Ashby 1972 {published data only}
    1. Ashby P, Burke D, Rao S, Jones RF. Assessment of cyclobenzaprine in the treatment of spasticity. Journal of Neurology, Neurosurgery and Psychiatry 1972;35:599‐605. - PMC - PubMed
Azouvi 1996 {published data only}
    1. Azouvi P, Mane M, Thiebaut JB, Denys P, Remy Neris O, Bussel B. Intrathecal baclofen administration for control of severe spinal spasticity: functional improvement and long‐term follow up. Archives of Physical Medicine and Rehabilitation 1996;77(1):35‐9. - PubMed
Basmajian 1973 {published data only}
    1. Basmajian JV, Super GA. Dantrolene sodium in the treatment of spasticity. Archives of Physical Medicine and Rehabilitation 1973;54(2):61‐4. - PubMed
Basmajian 1974 {published data only}
    1. Basmajian JV, Yucel V. Effects of a GABA‐derivative (BA‐34647) on spasticity. Preliminary report of a double‐blind cross‐over study. American Journal of Physical Medicine 1974;53(5):223‐8. - PubMed
Bokonjic 1979 {published data only}
    1. Bokonjic R, Dimitrijevic J. Medication of spasticity with a combination of glycine and folic acid ‐ double blind study] [Medikacija spasticnosti sa kombinacijom glicin folna kiselina ‐ duplo slijepa studija.]. Medicinski Arhiv 1979;33:403‐6. - PubMed
Bovier 1985 {published data only}
    1. Bovier P, Cambier J, Morselli PL. Double blind study of progabide in spasticity [Etude en double‐aveugle du progabide dans la spasticite]. Therapie 1985;40:181‐5. - PubMed
Broseta 1989 {published data only}
    1. Broseta J, Morales F, Garcia March G, Sanchez Ledesma MJ, Anaya J, Gonzalez Darder J, et al. Use of intrathecal baclofen administered by programmable infusion pumps in resistant spasticity. Acta Neurochirurgica. Supplementum (Wien) 1989;46:39‐45. - PubMed
Chan 1994 {published data only}
    1. Chan A, Hugos C, Morrison S, Theriot K. Balance and Spasticity: what we know and what we believe. Journal of Neurologic Rehabilitation 1994;8:119‐30.
Cocchiarella 1967 {published data only}
    1. Cocchiarella A, Downey JA, Darling RC. Evaluation of the effect of diazepam on spasticity. Archives of Physical Medicine and Rehabilitation 1967;48:393‐6. - PubMed
Coffey 1993 {published data only}
    1. Abel NA, Smith RA. Intrathecal baclofen for treatment of intractable spinal spasticity. Archives of Physical Medicine and Rehabilitation 1994;75:54‐8. - PubMed
    1. Coffey JR, Cahill D, Steers W, Park TS, Ordia J, Meythaler J, et al. Intrathecal baclofen for intractable spasticity of spinal origin: results of a long‐term multicenter study. Journal of Neurosurgery 1993;78:226‐32. - PubMed
Cohan 1980 {published data only}
    1. Cohan SL, Raines A, Panagakos J, Armitage P. Phenytoin and Chlorpromazine in the treatment of spasticity. Archives of Neurology 1980;37:360‐4. - PubMed
Donovan 2000 {published data only}
    1. Donovan WH, Halter JA, Graves DE, Blight AR, Calvillo MT, McCann MT, et al. Intravenous infusion of 4‐AP in chronic spinal cord injured subjects. Spinal Cord 2000;38:7‐15. - PubMed
Fung 1990 {published data only}
    1. Fung J, Stewart JE, Barbeau H. The combined effects of clonidine and cyproheptadine with interactive training on the modulation of locomotion in spinal cord injured subjects. Journal of the Neurological Sciences 1990;100:85‐93. - PubMed
Glass 1974 {published data only}
    1. Glass A, Hannah A. A comparison of dantrolene sodium and diazepam in the treatment of spasticity. Paraplegia 1974;12:170‐4. - PubMed
Growdon 1991 {published data only}
    1. Growdon JH, Nader TM, Schoenfeld J, Wurtman RJ. L‐threonine in the treatment of spasticity. Clinical Neuropharmacology 1991;14:403‐12. - PubMed
Harvey 1974 {published data only}
    1. Harvey MS. A comparative trial of dimethothiazine in spastic conditions. The Practitioner 1974;213:101‐5. - PubMed
Haslam 1974 {published data only}
    1. Haslam RH, Walcher JR, Lietman PS, Kallman CH, Mellitis ED. Dantrolene sodium in children with spasticity. Archives of Physical Medicine and Rehabilitation 1974;55:384‐8. - PubMed
Hinderer 1990 {published data only}
    1. Hinderer SR. The supraspinal anxiolytic effect of baclofen for spasticity reduction. American Journal of Physical Medicine and Rehabilitation 1990;69(5):254‐7. - PubMed
    1. Hinderer SR, Lehmann JF, Price R, White O, deLateur BJ, Deitz J. Spasticity in spinal cord injured persons: quantitative effects of baclofen and placebo treatments. American Journal of Physical Medicine and Rehabilitation 1990;69:311‐7. - PubMed
Hudgson 1971 {published data only}
    1. Hudgson P, Weightman D. Baclofen in the treatment of spasticity. British Medical Journal 1971;4:131‐4. - PMC - PubMed
Hudgson 1972 {published data only}
    1. Hudgson P, Weightman D, Cartlidge NE. Clinical trial of baclofen against placebo. Postgraduate Medical Journal 1972;Suppl 5:37‐40. - PubMed
Lee 1993 {published data only}
    1. Lee A, Patterson V. A double‐blind study of L‐threonine in patients with spinal spasticity. Acta Neurologica Scandinavica 1993;88(5):334‐8. - PubMed
Levine 1968 {published data only}
    1. Levine IM, Jossmann PB, Rudd J, Angelis V. The quantitative evaluation of intravenous methocarbamol in the relief of spasticity. Neurology 1968;18:69‐74. - PubMed
Levine 1969 {published data only}
    1. Levine IM, Jossmann PB, Friend DG, Angelis V. Prazepam in the treatment of spasticity. A quantitative double‐blind evaluation. Neurology 1969;19:510‐6. - PubMed
Levine 1977 {published data only}
    1. Levine IM, Jossmann PB, DeAngelis V. Lioresal, a new muscle relaxant in the treatment of spasticity‐a double‐blind quantitative evaluation. Diseases of the Nervous System 1977;38:1011‐5. - PubMed
Losin 1966 {published data only}
    1. Losin S, McKean CM. Chlorzoxazone (paraflex) in the treatment of severe spasticity. Developmental Medicine and Child Neurology 1966;8:768‐9. - PubMed
Lossius 1985 {published data only}
    1. Lossius R, Dietrichson P, Lunde PK. Effect of clorazeprate in spasticity and rigidity: a quantitative study of reflexes and plasma concentrations. Acta Neurologica Scandinavica 1985;71:190‐4. - PubMed
Maurer 1990 {published data only}
    1. Maurer M, Henn V, Dittrich A, Hofmann A. Delta‐9‐tetahydrocannabinol shows antispastic and analgesic effects in a single case double‐blind trial. European Archives of Psychiatry and Neurological Sciences 1990;240:1‐4. - PubMed
Middel 1997 {published data only}
    1. Middel B, Kuipers‐Upmeijer H, Bouma J, Staal M, Oenema D, Postma T, et al. Effect of intrathecal baclofen delivered by an implanted programmable pump on health related quality of life in patients with severe spasticity. Journal of Neurology, Neurosurgery and Psychiatry 1997;63:204‐9. - PMC - PubMed
Monster 1973 {published data only}
    1. Monster AW. Spasticity and the effect of dantrolene sodium. Archives of Physical Medicine and Rehabilitation 1974;55:373‐83. - PubMed
    1. Monster AW, Herman R, Meeks S, McHenry J. Cooperative study for assessing the effects of a pharmacological agent on spasticity. American Journal of Physical Medicine 1973;52:163‐88. - PubMed
Nance 1989 {published data only}
    1. Nance PW, Shears AH, Nance DM. Reflex changes induced by clonidine in spinal cord injured patients. Paraplegia 1989;27:296‐301. - PubMed
Nance 1994a {published data only}
    1. Nance PW. A comparison of clonidine, cyproheptadine and baclofen in spastic spinal cord injured patients. Journal of the American Paraplegia Society 1994;17:150‐6. - PubMed
O'Brien 1995 {published data only}
    1. O'Brien CF, Simpson DM, Alexander D, Tagliati M, Aswad AS, Gibson J, et al. A randomised double blind placebo controlled study to evaluate the use of botulinum toxin type A in the treatment of spasticity. Neurology 1995;45 Suppl 4:A329. - PubMed
Ordia 1996 {published data only}
    1. Ordia JI, Fischer E, Adamski E, Spatz EL. Chronic intrathecal delivery of baclofen by a programmable pump for the treatment of severe spasticity. Journal of Neurosurgery 1996;85:452‐7. - PubMed
Pagano 1990 {published data only}
    1. Pagano MA, Ferreiro ME, Herskovits E. Comparative study of tizanidine and baclofen in patients with chronic spasticity [Estudio comparativo de tizanidina con baclofen en pacientes con espesticidad cronica]. Revista Neurologia Argentina 1990;15:27‐33.
Parke 1989 {published data only}
    1. Parke B, Penn RD, Savoy SM, Corcos D. Functional outcomes after delivery of intrathecal baclofen. Archives of Physical Medicine and Rehabilitation 1989;70:30‐2. - PubMed
Pedersen 1970 {published data only}
    1. Pedersen E, Arlien Soborg P, Grynderup V, Henriksen O. Gaba derivative in spasticity (Beta‐(4‐chlorophenyl)‐gamma‐aminobutyric acid, Ciba 34.647‐Ba). Acta Neurologica Scandinavica 1970;46:257‐66. - PubMed
Pirotte 1995 {published data only}
    1. Pirotte B, Heilporn A, Joffroy A, Zegers de Beyl D, Wesel P, Brotchi J, et al. Chronic intrathecal baclofen in severely disabling spasticity: selection, clinical assessment and long‐term benefit. Acta Neurologica Belgica 1995;95:216‐25. - PubMed
Postma 1999 {published data only}
    1. Postma TJ, Oenema D, Terpstra S, Bouma J, Kuipers‐Upmeijer H, Staal MJ, et al. Cost analysis of the treatment of severe spinal spasticity with a continuous intrathecal baclofen infusion system. Pharmacoeconomics 1999;15(4):395‐404. [PUBMED: 10537958] - PubMed
Priebe 1997 {published data only}
    1. Priebe MM, Sherwood AM, Graves DE, Mueller M, Olson WH. Effectiveness of gabapentin in controlling spasticity: a quantitative study. Spinal Cord 1997;35:171‐5. - PubMed
Richardson 2000 {published data only}
    1. Richardson D, Sheen G, Werring D, Desai M, Edwards S, Greenwood R, et al. Evaluating the role of botulinum toxin in the management of focal hypertonia in adults. Journal of Neurology Neurosurgery and Psychiatry 2000;69(4):499‐506. - PMC - PubMed
Roussan 1985 {published data only}
    1. Roussan M, Terrence C, Fromm G. Baclofen versus diazepam for the treatment of spasticity and long‐term follow‐up of baclofen therapy. Pharmatherapeutica 1985;4:278‐84. - PubMed
Schmidt 1976 {published data only}
    1. Schmidt RT, Lee RH, Spehlmann R. Comparison of dantrolene sodium and diazepam in the treatment of spasticity. Journal of Neurology Neurosurgery and Psychiatry 1976;33:403‐6. - PMC - PubMed
Segal 1999 {published data only}
    1. Segal JL, Pathak MS, Hernandez JP, Himber PL, Brunnemann SR, Charter RS. Safety and efficacy of 4‐aminopyridine in humans with spinal cord injury: a long‐term, controlled trial. Pharmacotherapy 1999;19(6):713‐23. - PubMed
Wainberg 1990 {published data only}
    1. Wainberg M, Barbeau H, Gauthier S. The effects of cyproheptadine on locomotion and on spasticity in patients with spinal cord injuries. Journal of Neurology Neurosurgery and Psychiatry 1990;53:754‐63. - PMC - PubMed
Weiser 1978 {published data only}
    1. Weiser R, Terenty T, Hudgson P, Weightman D. Dantrolene sodium in the treatment of spasticity in chronic spinal cord disease. Practitioner 1978;221:123‐7. - PubMed
Wilson 1966 {published data only}
    1. Wilson LA, McKechnie AA. Oral diazepam in the treatment of spasticity in paraplegia a double‐blind trial and subsequent impressions. Scottish Medical Journal 1966;11:46‐51. - PubMed

Additional references

Bohannon 1987
    1. Bohannon RW, Smith MNB. Interrater reliability of modified Ashworth scale of muscle spasticity. Physical Therapy 1987;67:206‐7. - PubMed
Campbell 2001
    1. Campbell FA, Tramer MR, Carroll D, Reynolds DJ, Moore RA, McQuay HJ. Are cannabinoids an effective and safe treatment option in the management of pain? A qualitative systematic review. BMJ 2001;323(7303):13‐6. - PMC - PubMed
Creedon 1997
    1. Creedon SD, Dijkers MP, Hinderer SR. Intrathecal baclofen for severe spasticity: a meta‐analysis. International Journal of Rehabilitation and Health 1997;3(3):171‐85.
Higgins 2008
    1. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.1 [updated September 2008]. The Cochrane Collaboration, 2008. Available from www.cochrane‐handbook.org.
Katz 1989
    1. Katz RT, Rymer WZ. Spastic hypertonia: mechanisms and measurement. Archives of Physical Medicine and Rehabilitation 1989;70:144‐55. - PubMed
Maynard 1990
    1. Maynard FM, Karunas RS, Waring WP. Epidemiology of spasticity following traumatic spinal cord injury. Archives of Physical Medicine and Rehabilitation 1990;71:566‐9. - PubMed
Noreau 2000
    1. Noreau L, Proulx P, Gagnon L, Drolet M, Laramee MT. Secondary impairments after spinal cord injury. A population‐based study. American Journal of Physical Medicine and Rehabilitation 2000;79(6):526‐41. - PubMed
Priebe 1996
    1. Priebe MM, Sherwood AM, Thornby JI, Kharas NF, Markowski J. Clinical assessment of spasticity in spinal cord injury: a multidimensional problem. Archives of Physical Medicine and Rehabilitation 1996;77:713‐6. - PubMed
Schultz 1995
    1. Schultz KF, Chalmers I, Hayes RJ, Altman DG. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 1995;273:408‐12. - PubMed
Walter 2002
    1. Walter JS, Sacks J, Othman R, Rankin AZ, Nemchausky B, Chintam R, et al. A database of self‐reported secondary medical problems among VA SCI patients: its role in clinical care and management. Journal of Rehabilitation Research and Development 2002;39(1):53‐61. - PubMed

Publication types

MeSH terms